Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies
Diana W. Shineman, Howard Fillit(Alzheimer's Drug Discovery Foundation), David Riddell(Pfizer (United States)), Kimberly Scearce‐Levie, Juha Yrjänheikki(Charles River Laboratories (Netherlands)), Gabrielle G. Leblanc(Cornell University), Patrick Sweeney(University of Illinois Urbana-Champaign), Linda H Lee(Alzheimer's Drug Discovery Foundation), Beth Hollister(Duke University), Barry Greenberg(University of California San Diego), John Lincecum(Amyotrophic Lateral Sclerosis Therapy Development Institute), Iva Morse(Charles River Laboratories (Netherlands)), Feng Luo(Abbott (United States)), Dave Morgan(University of South Florida), Guriqbal S. Basi(Sunesis (United States)), Jennifer L. Bizon(University of Florida), Lorenzo M. Refolo(National Institute on Aging), Carol A. Colton(Duke Medical Center)
Cited by 135
Related Papers
A gene expression atlas of the central nervous system based on bacterial artificial chromosomes
|Nature|2003|2.2k
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
|Stroke|2006|1.7k
Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain
|Journal of Neuroimmune Pharmacology|2009|872
Protein misfolding in neurodegenerative diseases: implications and strategies
|Translational Neurodegeneration|2017|671